Don't overthink it just drink enough
Theoretical concerns The limited human research on these peptides means some potential concerns remain theoretical: Cancer risk: Any peptide that promotes cell proliferation and blood vessel formation raises questions about potential effects on existing tumors
Regular check-ups can assess the effectiveness of the treatment and make necessary modifications
For individuals who have experienced immunogenic reactions to other therapeutic proteins or peptides, AOD-9604s demonstrated lack of immunogenicity may represent a favorable characteristic
Typical Cycle Lengths Mild to moderate injury (tendon, ligament, muscle): 24 weeks at 250500mcg per day Severe or post-operative injuries: 46 weeks, sometimes extending to 8 weeks Gastrointestinal issues (ulcers, IBS): 46 weeks at 250500mcg per day, oral or subQ Neurological repair or systemic inflammation: 46 weeks, systemic dosing recommended For most users, results begin to show within the first 710 days , especially in soft tissue or gut repair cases
Oral administration is the most logical route for gut-focused applications, since the peptide is uniquely stable in gastric juice